Preferred Label : Enfortumab Vedotin/Pembrolizumab Regimen;
NCIt synonyms : Pembrolizumab/Enfortumab Vedotin Regimen; Enfortumab Vedotin-Pembrolizumab; Enfortumab Vedotin-ejfv/Pembrolizumab Regimen; Enfortumab Vedotin-ejfv-Pembrolizumab; Keytruda/Padcev Regimen; Padcev/Keytruda Regimen;
NCIt related terms : Enfortumab vedotin and Pembrolizumab;
NCIt definition : A regimen consisting of enfortumab vedotin and pembrolizumab that can be used for
the treatment of bladder cancer.;
NCI Metathesaurus CUI : CL1922493;
Codes from synonyms : 120168;
Origin ID : C203692;
UMLS CUI : C5909404;
Semantic type(s)
- chemotherapy_regimen_has_component
- concept_is_in_subset
https://www.has-sante.fr/jcms/p_3546650/fr/padcev-enfortumab-vedotin-carcinome-urothelial
2024
false
false
false
France
Enfortumab Vedotin/Pembrolizumab Regimen
treatment outcome
insurance, health, reimbursement
urologic neoplasms
antineoplastic combined chemotherapy protocols
pembrolizumab
Metastatic Urothelial Carcinoma
Unresectable Urothelial Carcinoma
adult
enfortumab vedotin
antineoplastic agents
evaluation of the transparency committee
carcinoma
enfortumab vedotin
---
https://www.has-sante.fr/jcms/p_3546684/fr/keytruda-pembrolizumab-carcinome-urothelial
2024
false
false
false
France
urologic neoplasms
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
Enfortumab Vedotin/Pembrolizumab Regimen
enfortumab vedotin
adult
Metastatic Urothelial Carcinoma
Unresectable Urothelial Carcinoma
pembrolizumab
evaluation of the transparency committee
carcinoma
pembrolizumab
---
